VanEck Pharmaceutical ETF (NASDAQ:PPH) Shares Sold by US Bancorp DE

US Bancorp DE lowered its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 53.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 873 shares of the company’s stock after selling 983 shares during the period. US Bancorp DE’s holdings in VanEck Pharmaceutical ETF were worth $75,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of PPH. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in VanEck Pharmaceutical ETF by 117.4% in the fourth quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 200,000 shares of the company’s stock valued at $17,256,000 after purchasing an additional 108,000 shares during the period. Adamsbrown Wealth Consultants LLC increased its position in shares of VanEck Pharmaceutical ETF by 102.3% during the fourth quarter. Adamsbrown Wealth Consultants LLC now owns 149,631 shares of the company’s stock valued at $12,910,000 after acquiring an additional 75,659 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of VanEck Pharmaceutical ETF by 33.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock valued at $22,322,000 after acquiring an additional 59,025 shares during the period. Blue Chip Partners LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 4th quarter worth approximately $2,139,000. Finally, Miller Investment Management LP increased its holdings in VanEck Pharmaceutical ETF by 13.4% in the 3rd quarter. Miller Investment Management LP now owns 207,535 shares of the company’s stock valued at $19,722,000 after purchasing an additional 24,446 shares during the last quarter.

VanEck Pharmaceutical ETF Stock Up 1.6 %

Shares of NASDAQ PPH opened at $93.29 on Tuesday. The business’s 50 day moving average is $89.72 and its two-hundred day moving average is $91.08. VanEck Pharmaceutical ETF has a 52-week low of $84.48 and a 52-week high of $99.51. The firm has a market cap of $582.13 million, a price-to-earnings ratio of 30.55 and a beta of 0.72.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently disclosed a dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 27th were issued a $0.411 dividend. The ex-dividend date was Friday, December 27th. This is an increase from VanEck Pharmaceutical ETF’s previous dividend of $0.36.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.